Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Images

Bullae And Blisters: A Rare Case of Bendamustine Skin Toxicity

Authors: Kamal Kant Sahu, Gitesh Upendra Sawatkar, Preethi Jeyaraman, Gaurav Prakash, Subhash C. Varma, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Excerpt

A-67-year old male was evaluated for unremitting fever of 6 months duration. Clinical examination revealed anaemia, hepatosplenomegaly and generalised lymphadenopathy. Lymph nodal biopsy and bone marrow examination showed features suggestive of mantle cell lymphoma (MCL). In view of poor performance status and old age, he was started on Bendamustine–Rituximab (BR) regimen (B-90 mg/m2 × 2 days and R-375 mg/m2). During the 1st cycle, after infusion of bendamustine, patient started developing skin lesions in the form of flaccid to tense blisters and bullae over an erythematous background, proximal to injection site on left hand (Fig. 1a, b). Lesions did not involve any other part of body. Eruptions were not associated with pruritus or fever and did not progress proximal to elbow joint. In the following week, lesions resolved on its own without any medication. The lesions reappeared soon after 2nd cycle in the similar pattern and subsided successively. As the patient did not develop any life threatening adverse events related to bendamustine, patient is being planned for 3rd cycle under close observation.
Literature
1.
go back to reference Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study groupindolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximabas first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210CrossRefPubMed Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study groupindolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximabas first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210CrossRefPubMed
2.
go back to reference Nishikori M, Kitano T, Kobayashi M, Hishizawa M, Kitawaki T, Kondo T, Yamashita K, Kawabata H, Kadowaki N, Takei Y, Haga H, Takaori-Kondo A (2015) Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol 102(1):53–58CrossRefPubMed Nishikori M, Kitano T, Kobayashi M, Hishizawa M, Kitawaki T, Kondo T, Yamashita K, Kawabata H, Kadowaki N, Takei Y, Haga H, Takaori-Kondo A (2015) Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol 102(1):53–58CrossRefPubMed
3.
go back to reference Gavini A, Telang GH, Olszewski AJ (2012) Generalized purpuric drug exanthemwithhemorrhagic plaques following bendamustine chemotherapy in a patient withB-prolymphocytic leukemia. Int J Hematol 95(3):311–314CrossRefPubMed Gavini A, Telang GH, Olszewski AJ (2012) Generalized purpuric drug exanthemwithhemorrhagic plaques following bendamustine chemotherapy in a patient withB-prolymphocytic leukemia. Int J Hematol 95(3):311–314CrossRefPubMed
4.
go back to reference Malipatil B, Ganesan P, Sundersingh S, Sagar TG (2011) Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Hematol Oncol Stem Cell Ther 4(4):157–160CrossRefPubMed Malipatil B, Ganesan P, Sundersingh S, Sagar TG (2011) Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Hematol Oncol Stem Cell Ther 4(4):157–160CrossRefPubMed
5.
go back to reference Nishikori M, Kitano T, Kobayashi M, Hishizawa M, Kitawaki T, Kondo T, Yamashita K, Kawabata H, Kadowaki N, Takei Y, Haga H, Takaori-Kondo A (2015) Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol 102(1):53–58CrossRefPubMed Nishikori M, Kitano T, Kobayashi M, Hishizawa M, Kitawaki T, Kondo T, Yamashita K, Kawabata H, Kadowaki N, Takei Y, Haga H, Takaori-Kondo A (2015) Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol 102(1):53–58CrossRefPubMed
Metadata
Title
Bullae And Blisters: A Rare Case of Bendamustine Skin Toxicity
Authors
Kamal Kant Sahu
Gitesh Upendra Sawatkar
Preethi Jeyaraman
Gaurav Prakash
Subhash C. Varma
Pankaj Malhotra
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0651-5

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine